New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, March 5, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Ariad Pharmaceuticals Inc. Analyst Notes
On February 21, 2014, Ariad Pharmaceuticals, Inc. (Ariad) announced that Alexander J. Denner, Ph.D. has been appointed to a two-year term on the Company's Board of Directors, effective immediately. The Company informed that he serves as the chief investment officer and founding partner of Sarissa Capital Management LP. Ariad stated that with the addition of Alexander J. Denner, Board of the Company now includes nine directors, including eight independent directors. The Company added that it will also appoint another independent director to the Board, to be selected by the Board and be subject to Dr. Denner's concurrence. Harvey J. Berger, M.D., Chairman and CEO of ARIAD, commented, "We welcome Dr. Denner to the Company's Board and look forward to working with him to continue building shareholder value, which we all believe is best achieved through successful commercialization of Iclusig® (ponatinib), as well as the ongoing development of our strong pipeline of important cancer medicines." The full analyst notes on Ariad Pharmaceuticals Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ARIA/report.pdf
--
Novavax, Inc. Analyst Notes
On February 27, 2014, Novavax, Inc. (Novavax) announced that a contract modification has been executed to extend the base period of performance of its current contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Novavax' recombinant seasonal and pandemic influenza vaccines. Commenting on the extension, Stanley C. Erck, the Company's CEO and President said, "While our original development plans anticipated utilizing the full amount of the contracted base-period funding within the three-year period, certain scope changes and development efforts resulted in delayed development timelines. Extending the base period allows us to continue to access the remaining base period budget as we initiate a pandemic H7N9 Phase 2 study early this year and prepare for additional Phase 2 and Phase 3 influenza clinical trials, which we expect would occur during the contract's option period." The full analyst notes on Novavax, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/NVAX/report.pdf
--
Fonar Corp. Analyst Notes
On February 27, 2014, Fonar Corp.'s (Fonar) stock increased 13.16% to end the day at $24.68 compared to the previous day's closing price of $21.81. The Company's stock increased 13.84% over the past three trading days, compared to the Nasdaq Composite, which rose 0.60% during the same trading period. The full analyst notes on Fonar Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/FONR/report.pdf
--
bluebird bio, Inc. Analyst Notes
On February 26, 2014, bluebird bio, Inc. (bluebird) announced that the Company's management will be presenting at the Cowen and Company 34th Annual Health Care Conference to be held on March 2 to 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, Massachusetts . The Company said that Nick Leschly, Chief bluebird, will provide an overview of the Company at the conference on March 4, 2014, Tuesday at 8:00 a.m. ET. bluebird added that simultaneous webcast of Mr. Leschly's overview can be accessed via "Calendar of Events" section on the Investor and Media page of the Company website, where a replay will also be available for ninety days following the conference. The full analyst notes on bluebird bio, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/BLUE/report.pdf
--
Cara Therapeutics Inc. Analyst Notes
On February 5, 2014, Cara Therapeutics Inc. (Cara) announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $11.00 per share, including the full exercise by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments. The Company stated that the net proceeds to Cara from the initial public offering were c.$55.9 million including the sale of the additional shares from the option and after deducting underwriting discounts and commissions and estimated offering expenses. The full analyst notes on Cara Therapeutics Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/CARA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article